Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF- α), prevents retinal ganglion cell loss in a rat model of glaucoma

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Roh, Miin ^a,b   Zhang, Yan ^a   Murakami, Yusuke ^a   Thanos, Aristomenis ^a   Lee, Sung Chul ^b   Vavvas, Demetrios G ^a   Benowitz, Larry I ^c   Miller, Joan W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; ETANERCEPT; NEUROFILAMENT L PROTEIN; NEUROFILAMENT M PROTEIN; NEUROFILAMENT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GLAUCOMA; IMMUNOHISTOCHEMISTRY; INTRAOCULAR HYPERTENSION; MALE; MICROGLIA; NERVE CELL NECROSIS; NERVE FIBER DEGENERATION; NONHUMAN; OPTIC NERVE DISEASE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RETINA GANGLION CELL;

ANIMALS; CELL DEATH; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GLAUCOMA; IMMUNOGLOBULIN G; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; RATS; RECEPTORS, TUMOR NECROSIS FACTOR; RETINAL GANGLION CELLS; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84863625033     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040065     Document Type: Article

References (65)

1. Quigley HA, (1999) Neuronal death in glaucoma. Prog Retin Eye Res 18: 39-57.
2. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M, (2002) Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120: 1268-1279.
3. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, et al. (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 701-713; discussion 829-730.
4. Weinreb RN, Khaw PT, (2004) Primary open-angle glaucoma. Lancet 363: 1711-1720.
5. Howell GR, Libby RT, Jakobs TC, Smith RS, Phalan FC, et al. (2007) Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J Cell Biol 179: 1523-1537.
6. Kaur C, Foulds WS, Ling EA, (2008) Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol 2: 879-889.
7. Tezel G, Yang X, Luo C, Cai J, Kain AD, et al. (2010) Hemoglobin expression and regulation in glaucoma: insights into retinal ganglion cell oxygenation. Invest Ophthalmol Vis Sci 51: 907-919.
8. Tezel G, Yang X, Luo C, Peng Y, Sun SL, et al. (2007) Mechanisms of immune system activation in glaucoma: oxidative stress-stimulated antigen presentation by the retina and optic nerve head glia. Invest Ophthalmol Vis Sci 48: 705-714.
9. Quigley HA, Addicks EM, Green WR, Maumenee AE, (1981) Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol 99: 635-649.
10. Hernandez MR, (1993) Extracellular Matrix Macromolecules of the Lamina Cribrosa: A Pressure-sensitive Connective Tissue. J Glaucoma 2: 50-57.
11. Yuan L, Neufeld AH, (2001) Activated microglia in the human glaucomatous optic nerve head. J Neurosci Res 64: 523-532.
12. Yuan L, Neufeld AH, (2000) Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia 32: 42-50.
13. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK, (1992) Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 149: 2736-2741.
14. Siu AW, Leung MC, To CH, Siu FK, Ji JZ, et al. (2002) Total retinal nitric oxide production is increased in intraocular pressure-elevated rats. Exp Eye Res 75: 401-406.
15. Smith CA, Farrah T, Goodwin RG, (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76: 959-962.
16. Harms AS, Barnum CJ, Ruhn KA, Varghese S, Trevino I, et al. (2011) Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Molecular therapy: the journal of the American Society of Gene Therapy 19: 46-52.
17. Yan X, Tezel G, Wax MB, Edward DP, (2000) Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch Ophthalmol 118: 666-673.
18. Tezel G, Wax MB, (2004) Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head. Arch Ophthalmol 122: 1348-1356.
19. Yang Z, Quigley HA, Pease ME, Yang Y, Qian J, et al. (2007) Changes in gene expression in experimental glaucoma and optic nerve transection: the equilibrium between protective and detrimental mechanisms. Invest Ophthalmol Vis Sci 48: 5539-5548.
20. Nakazawa T, Nakazawa C, Matsubara A, Noda K, Hisatomi T, et al. (2006) Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 26: 12633-12641.
21. Nanda S, Bathon JM, (2004) Etanercept: a clinical review of current and emerging indications. Expert Opin Pharmacother 5: 1175-1186.
22. Ramiro S, Radner H, van der Heijde D, van Tubergen A, Buchbinder R, et al. (2011) Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane database of systematic reviews.
23. Avunduk MC, Avunduk AM, Oztekin E, Baltaci AK, Ozyazgan Y, et al. (2004) Etanercept treatment in the endotoxin-induced uveitis of rats. Exp Eye Res 79: 357-365.
24. Sawada H, Fukuchi T, Tanaka T, Abe H, (2010) Tumor necrosis factor-alpha concentrations in the aqueous humor of patients with glaucoma. Invest Ophthalmol Vis Sci 51: 903-906.
25. Kreutzberg GW, (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19: 312-318.
26. Tochel CM, Morton JS, Jay JL, Morrison JD, (2005) Relationship between visual field loss and contrast threshold elevation in glaucoma. BMC ophthalmology 5: 22.
27. Pang IH, Clark AF, (2007) Rodent models for glaucoma retinopathy and optic neuropathy. J Glaucoma 16: 483-505.
28. McKinnon SJ, Schlamp CL, Nickells RW, (2009) Mouse models of retinal ganglion cell death and glaucoma. Exp Eye Res 88: 816-824.
29. Sande PH, Fernandez DC, Aldana Marcos HJ, Chianelli MS, Aisemberg J, et al. (2008) Therapeutic effect of melatonin in experimental uveitis. Am J Pathol 173: 1702-1713.
30. Chen YN, Yamada H, Mao W, Matsuyama S, Aihara M, et al. (2007) Hypoxia-induced retinal ganglion cell death and the neuroprotective effects of beta-adrenergic antagonists. Brain Res 1148: 28-37.
31. Schmidt KG, Pillunat LE, Osborne NN, (2004) [Ischemia and hypoxia. An attempt to explain the different rates of retinal ganglion cell death in glaucoma]. Ophthalmologe 101: 1071-1075.
32. Chung HS, Harris A, Evans DW, Kagemann L, Garzozi HJ, et al. (1999) Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv Ophthalmol 43: S43-50.
33. Streit WJ, (2005) Microglia and neuroprotection: implications for Alzheimer's disease. Brain Res Brain Res Rev 48: 234-239.
34. Walter L, Neumann H, (2009) Role of microglia in neuronal degeneration and regeneration. Semin Immunopathol 31: 513-525.
35. Fischer F, Martin G, Agostini HT, (2011) Activation of retinal microglia rather than microglial cell density correlates with retinal neovascularization in the mouse model of oxygen-induced retinopathy. J Neuroinflammation 8: 120.
36. Ito D, Tanaka K, Suzuki S, Dembo T, Fukuuchi Y, (2001) Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 32: 1208-1215.
37. Plange N, Kaup M, Doehmen B, Remky A, Arend KO, (2010) Fluorescein leakage of the optic disc: time course in primary open-angle glaucoma. Ophthalmic Physiol Opt 30: 315-320.
38. Arend O, Remky A, Plange N, Kaup M, Schwartz B, (2005) Fluorescein leakage of the optic disc in glaucomatous optic neuropathy. Graefes Arch Clin Exp Ophthalmol 243: 659-664.
39. Mangan BG, Al-Yahya K, Chen CT, Gionfriddo JR, Powell CC, et al. (2007) Retinal pigment epithelial damage, breakdown of the blood-retinal barrier, and retinal inflammation in dogs with primary glaucoma. Vet Ophthalmol 10: 117-124.
40. Pena JD, Agapova O, Gabelt BT, Levin LA, Lucarelli MJ, et al. (2001) Increased elastin expression in astrocytes of the lamina cribrosa in response to elevated intraocular pressure. Invest Ophthalmol Vis Sci 42: 2303-2314.
41. Uchihara T, Akiyama H, Kondo H, Ikeda K, (1997) Activated microglial cells are colocalized with perivascular deposits of amyloid-beta protein in Alzheimer's disease brain. Stroke 28: 1948-1950.
42. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, et al. (2001) Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35: 72-79.
43. Janelsins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, et al. (2008) Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3×Tg-AD mice. Am J Pathol 173: 1768-1782.
44. Tezel G, Wax MB, (2000) Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci 20: 8693-8700.
45. Tezel G, Li LY, Patil RV, Wax MB, (2001) TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 42: 1787-1794.
46. Bai Y, Shi Z, Zhuo Y, Liu J, Malakhov A, et al. (2010) In glaucoma the upregulated truncated TrkC.T1 receptor isoform in glia causes increased TNF-alpha production, leading to retinal ganglion cell death. Invest Ophthalmol Vis Sci 51: 6639-6651.
47. Lebrun-Julien F, Duplan L, Pernet V, Osswald I, Sapieha P, et al. (2009) Excitotoxic death of retinal neurons in vivo occurs via a non-cell-autonomous mechanism. J Neurosci 29: 5536-5545.
48. Bosco A, Steele MR, Vetter ML, (2011) Early microglia activation in a mouse model of chronic glaucoma. J Comp Neurol 519: 599-620.
49. Ebneter A, Casson RJ, Wood JP, Chidlow G, (2010) Microglial activation in the visual pathway in experimental glaucoma: spatiotemporal characterization and correlation with axonal injury. Invest Ophthalmol Vis Sci 51: 6448-6460.
50. Kreutz MR, Weise J, Dieterich DC, Kreutz M, Balczarek P, et al. (2004) Rearrangement of the retino-collicular projection after partial optic nerve crush in the adult rat. Eur J Neurosci 19: 247-257.
51. Harms AS, Lee JK, Nguyen TA, Chang J, Ruhn KM, et al. (2012) Regulation of microglia effector functions by tumor necrosis factor signaling. Glia 60: 189-202.
52. Ju KR, Kim HS, Kim JH, Lee NY, Park CK, (2006) Retinal glial cell responses and Fas/FasL activation in rats with chronic ocular hypertension. Brain Res 1122: 209-221.
53. Gregory MS, Hackett CG, Abernathy EF, Lee KS, Saff RR, et al. (2011) Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death. PloS one 6: e17659.
54. Buckingham BP, Inman DM, Lambert W, Oglesby E, Calkins DJ, et al. (2008) Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J Neurosci 28: 2735-2744.
55. Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT, (2005) Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 331: 134.
56. Morrison JC, Johnson EC, Cepurna W, Jia L, (2005) Understanding mechanisms of pressure-induced optic nerve damage. Prog Retin Eye Res 24: 217-240.
57. Shareef SR, Garcia-Valenzuela E, Salierno A, Walsh J, Sharma SC, (1995) Chronic ocular hypertension following episcleral venous occlusion in rats. Exp Eye Res 61: 379-382.
58. Mittag TW, Danias J, Pohorenec G, Yuan HM, Burakgazi E, et al. (2000) Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 41: 3451-3459.
59. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, et al. (2002) Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16: 438-440.
60. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, et al. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130: 478-486.
61. Moreland LW, McCabe DP, Caldwell JR, Sack M, Weisman M, et al. (2000) Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J Rheumatol 27: 601-609.
62. Cui Q, Yip HK, Zhao RC, So KF, Harvey AR, (2003) Intraocular elevation of cyclic AMP potentiates ciliary neurotrophic factor-induced regeneration of adult rat retinal ganglion cell axons. Mol Cell Neurosci 22: 49-61.
63. Yin Y, Cui Q, Li Y, Irwin N, Fischer D, et al. (2003) Macrophage-derived factors stimulate optic nerve regeneration. J Neurosci 23: 2284-2293.
64. Marina N, Bull ND, Martin KR, (2010) A semiautomated targeted sampling method to assess optic nerve axonal loss in a rat model of glaucoma. Nat Protoc 5: 1642-1651.
65. Trichonas G, Manola A, Morizane Y, Thanos A, Koufomichali X, et al. (2010) A novel nonradioactive method to evaluate vascular barrier breakdown and leakage. Invest Ophthalmol Vis Sci 51: 1677-1682.